EE87 Economic Evauation of Adalimumab Biosimilars and JAK Inhibitors for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.340
https://www.valueinhealthjournal.com/article/S1098-3015(22)00541-1/fulltext
Title :
EE87 Economic Evauation of Adalimumab Biosimilars and JAK Inhibitors for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00541-1&doi=10.1016/j.jval.2022.04.340
First page :
Section Title :
Open access? :
No
Section Order :
10296